Global Retirement Partners LLC boosted its holdings in Merck & Co., Inc. (NYSE:MRK) by 4.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 13,806 shares of the company’s stock after purchasing an additional 553 shares during the quarter. Global Retirement Partners LLC’s holdings in Merck & Co., Inc. were worth $1,129,000 at the end of the most recent quarter.
A number of other hedge funds have also modified their holdings of MRK. Nuveen Asset Management LLC grew its stake in Merck & Co., Inc. by 16.7% in the third quarter. Nuveen Asset Management LLC now owns 20,139,807 shares of the company’s stock valued at $1,670,597,000 after acquiring an additional 2,882,982 shares during the period. Samlyn Capital LLC acquired a new stake in Merck & Co., Inc. in the third quarter valued at approximately $97,609,000. DekaBank Deutsche Girozentrale grew its stake in Merck & Co., Inc. by 34.5% in the third quarter. DekaBank Deutsche Girozentrale now owns 3,888,808 shares of the company’s stock valued at $317,431,000 after acquiring an additional 996,562 shares during the period. Candriam Luxembourg S.C.A. grew its stake in Merck & Co., Inc. by 43.9% in the third quarter. Candriam Luxembourg S.C.A. now owns 2,934,202 shares of the company’s stock valued at $243,382,000 after acquiring an additional 895,634 shares during the period. Finally, Two Sigma Advisers LP grew its stake in Merck & Co., Inc. by 16.1% in the second quarter. Two Sigma Advisers LP now owns 5,174,899 shares of the company’s stock valued at $400,175,000 after acquiring an additional 717,100 shares during the period. Institutional investors and hedge funds own 66.43% of the company’s stock.
A number of equities research analysts have commented on the company. SVB Leerink raised their price objective on Merck & Co., Inc. from $100.00 to $103.00 and gave the company an “outperform” rating in a research note on Thursday, October 29th. Truist began coverage on Merck & Co., Inc. in a research report on Friday, October 23rd. They set a “buy” rating and a $96.00 target price on the stock. ValuEngine cut Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research report on Thursday, October 1st. Berenberg Bank began coverage on Merck & Co., Inc. in a research report on Tuesday, September 29th. They set a “hold” rating and a $88.00 target price on the stock. Finally, Mizuho reaffirmed a “buy” rating and set a $100.00 target price on shares of Merck & Co., Inc. in a research report on Sunday, December 6th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and twelve have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $95.36.
Shares of MRK opened at $82.34 on Thursday. The firm has a market cap of $208.32 billion, a PE ratio of 18.22, a PEG ratio of 1.96 and a beta of 0.43. The stock’s fifty day moving average price is $81.41 and its two-hundred day moving average price is $81.11. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.30 and a quick ratio of 1.00. Merck & Co., Inc. has a 1 year low of $65.25 and a 1 year high of $92.06.
Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, October 27th. The company reported $1.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.44 by $0.30. The firm had revenue of $12.55 billion for the quarter, compared to analyst estimates of $12.21 billion. Merck & Co., Inc. had a return on equity of 53.83% and a net margin of 24.33%. The business’s revenue was up 1.2% on a year-over-year basis. During the same period in the previous year, the company posted $1.51 earnings per share. Sell-side analysts anticipate that Merck & Co., Inc. will post 5.9 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Friday, January 8th. Shareholders of record on Tuesday, December 15th were paid a $0.65 dividend. The ex-dividend date was Monday, December 14th. This is a positive change from Merck & Co., Inc.’s previous quarterly dividend of $0.61. This represents a $2.60 annualized dividend and a dividend yield of 3.16%. Merck & Co., Inc.’s payout ratio is presently 50.10%.
Merck & Co., Inc. Profile
Merck & Co, Inc provides healthcare solutions worldwide. The company offers therapeutic and preventive agents for cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products.
Further Reading: What are the benefits of a balanced fund?
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.